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The lincRNA MIRAT binds to 
IQGAP1 and modulates the 
MAPK pathway in NRAS mutant 
melanoma
Martina Sanlorenzo1,2,3, Igor Vujic1,4,5, Rosaura Esteve-Puig  1, Kevin Lai1, Marin Vujic  1,  
Kevin Lin1, Christian Posch  1,4,5, Michelle Dimon1, Adrian Moy1, Mitchell Zekhtser1, 
Katia Johnston1, Deborah Gho1, Wilson Ho1, Abhinay Gajjala1, Juan Oses Prieto  6, 
Alma Burlingame6, Adil Daud  7, Klemens Rappersberger2,5 & Susana Ortiz-Urda1
Despite major advances in targeted melanoma therapies, drug resistance limits their efficacy. Long 
noncoding RNAs (lncRNAs) are transcriptome elements that do not encode proteins but are important 
regulatory molecules. LncRNAs have been implicated in cancer development and response to different 
therapeutics and are thus potential treatment targets; however, the majority of their functions and 
molecular interactions remain unexplored. In this study, we identify a novel cytoplasmic intergenic 
lincRNA (MIRAT), which is upregulated following prolonged MAPK inhibition in NRAS mutant 
melanoma and modulates MAPK signaling by binding to the MEK scaffold protein IQGAP1. Collectively, 
our results present MIRAT’s direct modulatory effect on the MAPK pathway and highlight the relevance 
of cytoplasmic lncRNAs as potential targets in drug resistant cancer.
Cutaneous melanoma is a highly aggressive cancer. In 2016, about 76380 individuals were diagnosed and 10130 
patients succumbed to metastatic disease in the United States1. Mutations in the v-Raf murine sarcoma viral 
oncogene homolog B1 (BRAF) and neuroblastoma rat sarcoma viral oncogene homolog (NRAS) are found in 
70–80% of all melanomas. These mutations cause anchorage independent activation of BRAF and NRAS pro-
teins which lead to hyperactive signaling through their downstream cascades, tumor growth and uncontrolled 
proliferation2. Recently, small molecule inhibitors targeting mutant BRAF and/or its immediate downstream 
signaling member MEK marked a milestone in the treatment of metastatic melanoma. Systemic therapy with 
BRAF-inhibitors such as vemurafenib and dabrafenib as well as MEK inhibitors such as cobimetinib and tra-
metinib have resulted in prolonged progression-free and overall survival3–8. Yet, most tumors become resistant 
to such targeted therapies, allowing disease progression. Several mechanisms of resistance to targeted inhibition 
have been described including: amplifications of receptor tyrosine kinases, RTKs (EGFR, ERBB3, IGFR1 and 
PDGFRb), secondary mutations in NRAS9, amplification of BRAFV600E or the expression of its alternative splic-
ing variant10, upregulation of COT (MAP3K8)11, mutations in MEK, and downregulation of SOX10 and MITF12 
among others. The role of long noncoding RNAs in such resistance, however, is still largely unknown10,13–17.
Long noncoding RNAs (lncRNAs) were identified as important parts of cell’s transcriptome and are thought 
to be regulatory elements of cancer initiation and progression. They are defined as RNA molecules longer then 
200 base pairs which are transcribed but not translated to proteins18,19. LncRNAs are highly tissue (and tumor) 
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specific and thus hold the potential for serving as biomarkers, prognostic indicators, and therapeutic targets20–25. 
The role of long noncoding RNAs in resistance of melanoma to targeted inhibition is poorly understood10,13–17.
In this study, we performed de novo transcriptome analyses (RNA-Seq) to identify lncRNAs differentially 
expressed in melanoma cells with acquired resistance to small molecule inhibitors of the MAPK cascade. By 
comparing treatment naïve cells to their drug resistant counterparts, we identified MIRAT (MAPK Inhibitor 
Resistance Associated Transcript), an lncRNA located on chromosome 8, significantly overexpressed in resistant 
cells. Analyses in NRAS mutant melanoma cells revealed MIRAT’s direct involvement in drug resistance to MAPK 
pathway inhibitors. Our results offer first evidence of a cytoplasmic lncRNA contributing to targeted inhibitor 
resistance in melanoma with the potential to open up new therapeutic avenues to further improve treatment.
Results
Acquired drug resistance to MAPK inhibitors in melanoma leads to the expression of the lin-
cRNA MIRAT (MAPK Inhibitor Resistance Associated Transcript). To assess whether acquired drug 
resistance changes the melanoma transcriptome, we first established cell lines with acquired resistance to small 
molecule inhibitors of BRAF and MEK. We treated 5 melanoma cell lines (2 NRASQ61 mutant: DO4, MM415; 3 
patients derived BRAFV600E mutant: AV1, AV4, AV5) with increasing dosages of the MEK inhibitor trametinib 
and the BRAF inhibitor PLX4720. After six months of continuous drug incubation, we compared the drug sen-
sitivities of treated clones with non-treated parental cells. Defined as a significant change in GI50 values (con-
centrations of drugs resulting in 50% growth inhibition relative to controls), 4 cell lines became resistant to the 
treatment (suffix RM; Resistant to MAPK inhibitor), while one cell line (AV5) remained sensitive to the treat-
ment (Suffix ChrExp; Chronically Exposed (Supplementary Fig. 1; for definition of resistant cell lines see mate-
rial and methods). Resistant cells MM415RM, DO4RM, AV1RM and AV4RM, but not the still drug sensitive 
AV5ChrExp, retained high signaling through the MAPK pathway despite increasing drug concentrations, as 
evidenced by high phospho-ERK levels (Supplementary Fig. 1).
Next, we performed paired-end RNA sequencing from the above-mentioned cell lines and compared the 
transcriptomes of resistant cell lines to their parental counterparts. The initial bioinformatics analysis provided 
a list of differentially expressed genes (Supplementary Material and Methods). These results were further fil-
tered with differentially expressed genes found in (i) acute (6 hours) trametinib treated cells (suffix A; Acutely 
treated) and (ii) chronically exposed cells (suffix ChrExp), to account for transcriptome changes after short-term 
and long-term drug exposures not leading to resistance (Supplementary Tables 1,2,3,4). Hierarchical cluster-
ing identified relationships among different conditions, and we found that resistant cell lines clustered together 
(Supplementary Fig. 2a; the heat-map illustrates the expression of differentially expressed genes). Surprisingly, 
after applying the different filters, only one lncRNA was differently expressed in all resistant clones (Fig. 1a,b). 
This lncRNA was intergenic (lincRNA) and mapped to the human chromosome 8q.24.12. We termed this tran-
script MIRAT: MAPK Inhibitor Resistance Associated Transcript (Supplementary Fig. 2b).
Probing for other, already known and probable mechanism of resistance to the MEK inhibitor trametinib we 
did not detect any additional NRAS mutations, SOX10 and MITF were not downregulated, and COT, BRAF and 
RTKs were not significantly upregulated in both NRAS mutant resistant cell lines. We did not find mutations in 
the coding regions of MEK1/2 and MEK1/2 RNA expression values and protein levels were comparable between 
parental and resistant cells (Supplementary Fig. 3)26. Due to low proliferation rates of patient derived avatar cell 
lines we performed all further experiments only in NRAS mutant DO4 and MM415 cell lines.
MIRAT is enriched in the cytoplasmatic compartment of MEK inhibitor resistant NRAS mutant 
melanoma cell lines and is found in patient samples. We focused our efforts on the further characteri-
zation of the newly identified transcript. We confirmed MIRAT’s presence in both NRAS and BRAF mutant resist-
ant cells by reverse transcription quantitative PCR (RT-qPCR) (Fig. 1c), and verified its exact sequence by Rapid 
Amplification of cDNA ends analysis (RACE). MIRAT has a 5′ cap and 3′ polyadenylated tail, indicating a tran-
scription by RNA polymerase II. The predicted secondary structure of MIRAT is depictured in Supplementary 
Fig. 4.27 Subcellular RNA isolation showed that MIRAT is primarily localized in the cytoplasmic cell compart-
ment, indicating transcript stability (Fig. 1d).
We found MIRAT exons expressed in 42 out of 226 (18,6%) TCGA melanoma patient samples included in the 
Atlas of ncRNA in Cancer (TANRIC)28 (Supplementary Table 5) and in 4 out of 19 (21,1%) melanoma biopsies 
from patients treated at our institution (21,1%) (Fig. 1e, Supplementary Table 6).
MIRAT is upregulated in a time- and dose-dependent manner in response to MAPK inhibition. 
Our RNA-Seq experiments detected MIRAT in drug-resistant melanoma cell lines but not in those treated for 
only 6 hours (DO4A, MM415A). To investigate the dynamics of MIRATs’ expression during time on drug the, we 
incubated cells with the MEK inhibitor trametinib and quantified MIRAT by RT-qPCR at different time points. 
MIRAT was upregulated as early as 24 hours after MEK inhibitor treatment, but at expression levels significantly 
lower than in resistant clones. Additionally, we found that MIRAT expression increased with higher trametinib 
doses (Fig. 2b). In parallel we tested the effect of the MEK inhibitor trametinib on the MAPK pathway and found 
a bimodal response to the drug with a p-ERK reduction during early drug incubation an its increase after 96 hours 
(Fig. 2a,b).
MIRAT could modulate the MAPK signaling pathway. Since MIRAT was expressed as early as 24 h 
after trametinib incubation and increased up to 500-fold in resistant clones (Fig. 2a), we investigated if MIRAT 
was involved in the modulation of the MAPK pathway signaling using transient gene over-expression and 
RNA-silencing assays.
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We transfected the DO4 melanoma cell line with the two most abundant MIRAT isoforms (isoforms 1 and 2). 
Forty-eight hours after transfection we measured ectopic MIRAT levels similar to those observed in DO4RM 
cells, and confirmed a prevalent cytoplasmatic location of the transcript (Supplementary Fig. 5). The ectopic 
MIRAT overexpression led to a relative signaling resistance to the MEK inhibitor trametinib, evidenced by higher 
phospho-ERK levels after trametinib exposure in transfected cells (Fig. 3a,b).
To test whether MIRAT silencing might increase signaling sensitivity to MAPK pathway inhibition, we used 
two independent RNA interference methods: a pool of customized siRNA and the endoribonuclease-prepared 
siRNAs (esiRNA). esiRNA, known to have less off-target effects than siRNA and to be particularly efficient in 
silencing noncoding transcripts29, was superior in depleting MIRAT compared to siRNA and was thus used for 
all further knockdown experiments (Supplementary Fig. 6). MIRAT depletion did not significantly affect cell 
viability in resistant cells (Supplementary Fig. 7) but led to reduced p-ERK levels in both resistant cell lines tested 
(Fig. 3c), while the DO4 cells were only minimally affected (Supplementary Fig. 8).
To assess signaling changes in response to MIRAT depletion in resistant cells, we performed gene expres-
sion analyses comparing cells treated with esiRNA targeting MIRAT to cells treated with control siRNA 
(Supplementary Dataset 1). ‘Cell surface receptor linked signal transduction’ was found to be the most affected 
biological process following MIRAT knock-down, supporting its involvement in MAPK related signaling events 
(Supplementary Fig. 9).
The effect of MIRAT on the MAPK signaling cascade could be mediated by IQGAP1. After we 
established MIRAT’s connection to receptor signaling and the MAPK pathway we aimed to identify its possible 
Figure 1. MIRAT is expressed in the cytoplasm of melanoma cells resistant to MAPK inhibitors. (a) 
Bioinformatic pipeline of RNAseq data: the comparison of resistant clones with their parental counterparts 
applying acute and chronic treatment filters led to the identification of one coding gene (SPOCK1) and one 
lncRNA (MIRAT) differently upregulated in resistant clones. Expression of MIRAT in melanoma cell lines 
and tissue samples was determined by PCR and RT-qPCR analyses. (b) Bar graph showing FPKM values of 
MIRAT in parental and corresponding resistant cell lines. (c) Bar graph displaying MIRAT expression relative 
to GAPDH determined by RT-qPCR analyses and real time SYBR Green amplification. (d) PCR and RT-
qPCR analyses of MIRAT were performed in subcellular cytosolic RNA extracts of D04 and D04RM cells. The 
expression of MIRAT is displayed as relative values to GAPDH. (e) Bar graph representing MIRAT expression 
relative to GAPDH in 19 melanoma patients.
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binding partners to elucidate molecular mechanisms by which MIRAT interconnects with the MAPK pathway. 
We used RNA Antisense Purification Mass-Spectrometry (RAP-MS) and RNA binding-protein immunoprecipi-
tation (RIP) to search for possible binding partners. Among possible binding candidates we focused on IQGAP1 
(Supplementary Fig. 10, Supplementary Dataset 2). IQGAP1 is a scaffold protein that binds to BRAF, MEK 
and ERK30 and is known to modulate their activity31. When we performed RIP experiments we found MIRAT 
enriched in the IQGAP1 immunoprecipitated products. As MIRAT was found in the negative control IgG-rabbit 
antibody conditions and in the SNRNP70 antibody (Rabbit polyclonal IgG) pull down (Supplementary Fig. 11).
Binding of IQGAP1 to MIRAT was confirmed by enriched MIRAT levels in RNA-protein extracts from 
IQGAP1 pull down experiments, but not in the immunoglobulin G (IgG)-mouse bound sample used as negative 
control (Fig. 3c). However, MIRAT was also found in the negative control IgG-rabbit antibody conditions and in 
the SNRNP70 antibody (Rabbit polyclonal IgG) pull down (Supplementary Fig. 11).
To verify if MIRAT and IQGAP1 are involved in modulating the MAPK pathway, we performed further gene 
silencing experiments. Knock-down of both, MIRAT and IQGAP1, led to decreased levels of p-ERK in both 
resistant cell lines (Fig. 3d).
Discussion
The studies of mechanisms of resistance to targeted small molecule inhibitors could lead to a better understand-
ing of tumor biology and thus improve therapeutic strategies. Different mechanisms of resistance as a response to 
MAPK inhibition have already been reported13,16,32–35, but only few studies have assessed the role of lncRNAs20. 
Here, we test how melanoma cell transcriptomes change following MAPK inhibitor treatment. We compare 
Figure 2. MIRAT gene expression increases in a time and dose dependent manner. (a) MIRAT is upregulated 
under MEK inhibitor treatment with trametinib and increases over time. PCR (top left) and RT-qPCR analyses 
(top right) of MIRAT in D04 cells treated with 5 nM of the MEK inhibitor at indicated time points (0, 24, 
48, 72 and 96 hours). RT-qPCR data is presented as the relative MIRAT expression normalized to GAPDH. 
Western blot analyses displaying signaling changes in D04 parental, drug-sensitive cells after MEK inhibitor 
treatment over time: p-ERK levels are reduced and recover over time; (b) Increasing doses of the MEK 
inhibitor trametinib correlate with MIRAT expression. PCR (left) and RT-qPCR analysis (right) of MIRAT 
were performed on cDNA from D04 cells with different concentrations of the MEK inhibitor (5 nM–1 mM) for 
96 hours (Right). Western blot analyses displaying signaling changes in D04 parental, drug-sensitive cells after 
MEK inhibitor treatment at different doses. Cells show a dose dependent reduction of p-ERK.
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treatment naïve, short-term treated, chronically drug exposed and drug resistant cell lines and identify the 
lncRNA MIRAT which seems to be implicated in MAPK signaling after targeted pathway inhibition.
MIRAT mapped to the human chromosome 8q.24.12, a region characterized by only a few protein-coding and 
several lncRNA genes. This region is known for multiple SNPs and genomic alterations associated with cancer 
and has emerged as an important region for genetic susceptibility to various malignancies such as breast, pros-
tate, bladder, colon, lung, ovaries, pancreas and brain cancer36. Our findings support the biological relevance and 
indicate that the region 8q.24 is associated with drug resistance in cancer. Although MIRAT has recently been 
annotated, its function and intracellular location has yet not been studied19.
We found that MIRAT is predominately present in the cytoplasm, which is in contrast to most other known 
lncRNAs37. MIRAT silencing and overexpression, as well as RNA-protein interaction results, indicate that this 
lncRNA modulates the MAPK signaling pathway, at least in the tested NRAS mutant melanoma cell lines. 
However, this modulation is not sufficient to account for large changes in cell viability and thus is only a part of 
multiple mechanisms of resistance following small molecule inhibitor treatment. The exact description of such 
mechanisms of resistance on genetic, epigenetic and protein levels is beyond the scope of this manuscript but 
further studies are warranted.
Our findings suggest that MIRAT functions by binding to the scaffold protein IQGAP1, which is an essential 
protein facilitating signaling from MEK to ERK30,31. IQGAP1 is known to be elevated in various cancers, and 
could serve as a potential therapeutic target, not only in melanoma but also in other cancers with hyper-activated 
MAPK signaling31,38–40. MIRAT could bind to IQGAP1 and stabilize it, decelerate its decay and thus facilitate 
Figure 3. MIRAT modulates MAPK signaling through IQGAP1 binding. (a) Ectopic expression of two 
MIRAT isoforms in D04 parental cells 48 hours post-transfection was determined by PCR (top) and RT-qPCR 
analysis (bottom) normalized to GAPDH housekeeping gene. (b) Immunoblot showing that MIRAT isoform 
2 overexpression results in higher p-ERK levels in D04 cells after MEK inhibition with trametinib compared to 
respective controls. (c) Bar graph representing MIRAT relative expression in RNA-protein extract of IQGAP1 
pull down. MIRAT was found enriched in the extract of DO4-RM and not in the negative control (IgG mouse). 
(d) Immunoblot showing that silencing of MIRAT and IQGAP1 by esiRNA results in lower p-ERK levels in 
MM415RM and D04RM trametinib-resistant cells.
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signaling through the MAPK pathway. Also the fact that MIRAT is elevated only 24 hours after MAPK inhibition, 
points towards a regulatory feedback mechanism.
Interestingly the microarray data shows mostly upregulated genes following MIRAT’s knockdown in both cell 
lines tested. This may be due to a variety of other regulatory mechanisms which follow slight changes in MAPK 
signaling or due to further still not discovered functions of MIRAT. Furthermore, we have to consider that silenc-
ing RNA off-target effects cannot be fully excluded.
Taken together, we describe a noncoding RNA directly involved but not leading to drug resistance to small 
molecule inhibitors. Our results highlight the relevance of cytoplasmic lncRNA for oncogenic signaling pathways, 
and suggest that MIRAT and its protein-binding partner IQGAP1 may serve as potential therapeutic targets in 
melanoma through their modulation of the MAPK pathway. Future strategies of improving target therapies in 
cancer are likely to involve selective interference with lincRNAs and their protein-binding partners.
Material and Methods
Cell culture and establishment of resistant clones. Human NRAS mutant DO4 and MM415 were pro-
vided by Boris Bastian, University of San Francisco, California. DO4 and MM415 harbor NRASQ61L mutation. 
Cell lines were maintained in RPMI 1640 media (UCSF Cell Culture Facility) supplemented with 10% (vol/vol) 
heat inactivated fetal bovine serum. Primary avatar cell lines (AV1, AV4, AV5) were obtained from metastases of 
BRAF mutant patients. All experimental protocols were approved by UCSF Human Research Protection Program 
Institutional Review Board (IRB# 12-0948), all patients signed informed consent, and methods were carried out 
in accordance with relevant guidelines and regulations. Cell lines were incubated at 37 °C under 5% CO2.
To establish resistant cell lines, NRAS and BRAF mutant cell lines were continuously exposed to increas-
ing concentrations of respectively MEK inhibitor (GSK1120212) (Selleckchem) and BRAF inhibitor PLX-4720 
(Selleckchem). Resistant clones were selected, maintained and propagated in a complete medium supplemented 
with drugs for 6 months. At the end of this time period, the drug sensitivity of the resulting clones was tested 
seeding cells in 96 well plates with a density of 3,000-5,000 cells per well, treating them with the respective inhib-
itor increasing concentrations. Cell viability was measured using CellTiter-Glo Luminiscent Cell Viability Assay 
(Promega; G7570), according to the manufacturer’s protocol. Luminescence was measured on the SynergyHT 
plate reader (BioTek) using Gen5 software (Version 1.11.5). All experiments were performed at least in tripli-
cates. Cell lines were defined resistant to a drug if GI50 values (concentrations of drugs resulting in 50% growth 
inhibition relative to controls) were increased by at least two-fold (calculated by CalcuSyn software (Biosoft, 
Cambridge, UK; Version 2.1)). Resistant clones were termed RM (Resistant to MAPKi): DO4-RM, MM415-RM, 
AV1-RM, and AV4-RM. AV5 cells did not acquire resistance, therefore the resulting clone after 6 months’ expo-
sure to PLX-4720 was termed ChrExp (Chronical Exposed)
Immunoblotting. Cell lysates were prepared in RIPA buffer supplemented with Halt protease and phos-
phatase inhibitor cocktail (Thermo Scientific). Equal amounts of protein, as measured by BCA protein assay, 
were resolved in 4–12% Bis-Tris NuPage gradient gels (Life Technologies) and transferred electrophoretically 
on a polyvinylidene difluoride 0.45-m membrane. Membranes were blocked for 1 h at room temperature in 5% 
bovine serum albumin (BSA) or non-fat milk in TBST before being incubated overnight at 4 °C with the primary 
antibodies. All primary antibodies were diluted 1:1,000 in 5% BSA or non-fat milk in TBST. After three washes 
of 5 min in TBST, secondary antibodies were diluted 1:3,000 in 5% non-fat milk in TBST and incubated for 1 h at 
room temperature. After another three washes in TBST, detection of the signal was achieved by incubating the 
membrane and exposing it on autoradiography films from Denville Scientific (Metuchen, NJ, USA). The primary 
antibodies used were: anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (no. 9101), anti-AKT (no. 9272), 
anti-phospho-AKT (Ser473) (no. 9271). The secondary antibodies: Amersham ECL anti-rabbit IgG, HRP-linked 
whole ab from donkey (no. NA934-1ML) and anti-mouse IgG, HRP-linked whole ab from donkey (no. NA931-
1ML) were purchased from GE Healthcare Life Sciences. Anti-ERK2 (C-14) (sc-154) was purchased from Santa 
Cruz Biotechnology. Anti-IQGAP1 (clone AF4) (no. 05-504) was purchased from EMD Millipore. Anti-MITF 
(C5) was purchased from ThermoFisher Scientific (no. MA5-14146).
Gene expression analysis. Total RNA was extracted using the miRNeasy Mini Kit (Qiagen, Hilden, 
Germany). RNA-Seq was performed for 12 cell lines and conditions: DO4, MM415, AV1, AV4, AV5 parental cell 
lines; DO4 and MM415 cells after short-term (6 hours) treatment with GSK1120212; DO4-RM, MM415-RM, 
AV1-RM, AV4-RM, and AV5 ChrExp. cDNA sequencing libraries were prepared using the Illumina TruSeq Total 
RNA Sample kit, which uses Ribo-Zero to deplete rRNA, leaving ncRNAs intact. Paired-end, 101-bp sequencing 
was performed by Centrillion Biosciencies Inc. (CA, US) on an Illumina HiSeq. 2000. Sequence reads are aligned 
to the human genome (hg19) using TopHat. Cuffdiff (version 2.1.1) was used with the RefSeq annotation (down-
loaded from UCSC Genome Browser, May 2013) to detect differentially expressed genes. The data have been 
deposited in NCBI’s Gene Expression Omnibus41 and are accessible through GEO Series accession number GSE 
99867 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE 99867).
Patient sample collection and RNA extraction. We selected a set of patient melanoma tumors formalin-fixed 
paraffin-embedded (FFPE) blocks from the tissue bank of our institution (University of California, San Francisco). All 
experimental protocols were approved by UCSF Human Research Protection Program Institutional Review Board (IRB# 
12-0948), patients signed informed consent, and procedures were carried out in accordance with relevant guidelines and 
regulations. RNA was extracted using RNeasy FFPE kit (Qiagen, Valencia, CA). RNA yield and A260/A280 ratio were 
monitored with a NanoDrop ND-1000 spectrometer (NanoDrop Technologies). We pre-amplified the transcripts and 
performed TaqMan-qRT-PCR. GAPDH was used as an endogenous control, and to express the relative abundance of 
the transcripts making a comparison between samples possible. Patient information was extracted retrospectively from 
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the electronic patient charts into an excel file, following patient anonymization. The TANRIC web application was used 
to test MIRAT expression among available TCGA melanoma samples accordingly to described methods28.
RACE analysis. SMARTer RACE 5′/3′ Kit (no. 634859) was purchased from Clontech Laboratories, Inc. 
The analysis was performed accordingly to the manufacturer’s protocol. Used sequences were: 5′ RACE sense: 
GATTACGCCAAGCTTACTGATCCTTGAATGGGTTGCTATAATTACATTTTAAAGAGT (Tm = 65 °C). 3′ 
RACE sense: GATTACGCCAAGCTTGGTCACCAGGGCTCTTCTTCTCGGA (Tm = 69.2 °C).
Cloning procedures. MIRAT cloning was designed and synthesized using the high-fidelity DNA polymer-
ase Phusion Hot Start Flex DNA polymerase, and cloned into pcDNA-DEST40 Gateway vector.
siRNA and esiRNA. For siRNA studies, we designed customized siRNAs against MIRAT and used Control 
siRNA and ON-TARGET plus Human IQGAP1 (8826) siRNA–SMARTpool (004694-00-0005) (Thermo Fisher 
Scientific, Waltham, USA).
Cell lines were plated in 96 well plates with a density of 4000–8000 cells per well. After 24 hours, cells were 
transfected at a final concentration of 25 nM of siRNA, using Lipofectamine 2000 (Invitrogen, CA, USA) as per 
manufacturer’s instructions and incubated for 72 h post transfection. All siRNA experiments were performed at 
least in triplicates.
For esiRNA, we designed esiRNA libraries as previously described42,43. Briefly, esiRNA library was designed 
using DEQOR (a web based tool for design of siRNAs44) choosing the optimal gene-silencing region for PCR 
(400bp-600bp), primer design, attaching the T7 RNA polymerase promotor to the 5′ end of each primer. 
esiRNA were synthesized with the following steps: template generation, in vitro transcription to generate long 
dsRNA, digestion to generate a pool of short dsRNAs, purification of esiRNA. Transfection was performed with 
Lipofectamine.
RIP assay and RNA antisense purification-mass spectrometry (RAP-MS). Magna RIPTM RNA-Binding 
Protein Immunoprecipitation Kit (no. 17–700) was performed to identify and validate the protein-binding partner 
of MIRAT, accordingly to the manufacturer’s protocol. RNA antisense purification and mass spectrometry were per-
formed as previously described20,45–48.
Subcellular fractionation. Subcellular fractionation and RNA purification for the localization of MIRAT 
were performed using the Cytoplasmic and nuclear RNA purification Kit (#2100,34700) according to the manu-
facturer’s protocol.
Oligonucleotide sequences 5′-3′, probes and primers. MIRAT I Forward: CTCGGAGGGCCCATGA and 
Reverse: GGGAGCAGAGGGGAATG; MIRAT II Forward: CGGAGAAGACAAGACG and Reverse: CCCATGGG 
CCCCTTAC. GAPDH Forward: AGAAGACTGTGGATGGCCCC and Reverse: AGGTCCACCACCCTGTTGC. 
MALAT1 Forward: AGAAGACTGTGGATGGCCCC and Reverse: AGGTCCACCACCCTGTTGC. MITF 
Forward: CGAGCTCATGGACTTTCCCTTA and Reverse: CTTGATGATCCGATTCACCAAA. MIRAT 
DNA Biotin-TEG3′ probes: 1-CATGGTGGAGGAAGTCATGG, 2-CTATGAGTCCGGCATTTGAA, 
3-CGCAGGATTTAGTCTGGTAG, 4-CATTGTCACACACTCTCCTC, 5-CCTCTGTACTGTGTCATTAC, 
6-ACTGATCCTTGAATGGGTTG, 7-AGCTCAGATTTCTCAATGCT, 8-ATTGCGTAGGTATGCGGAAT.
Microarray analysis. Microarray analysis was performed using the GeneChip Human Gene 2.0 ST Array 
(902112) (Affymetrix, Thermo Fisher Scientific, Santa Clara, CA, USA) according to the manufacturer’s protocol. 
For experimental design and data analysis see Supplementary Fig. 5.
Statistical analyses. The statistical analyses were performed using Graphpad Prism V.7.0c and Stata 12.0 
statistical software. Comparisons between two independent non-normally distributed groups were performed 
using the nonparametric Wilcoxon rank-sum test; P values less than 0.05 were considered statistically significant.
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